SCHEMBL4606486

SCHEMBL4606486

CC/C(=C\c1ccc(Cl)cc1)C(=O)C(=O)O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIK1 P39086 1/20 0.53
CYP2C9 P11712 1/20 0.50
HDAC3 O15379 1/20 0.45
HDAC4 P56524 1/20 0.45
HDAC1 Q13547 1/20 0.45
HDAC7 Q8WUI4 1/20 0.45
HDAC2 Q92769 1/20 0.45
HDAC10 Q969S8 1/20 0.45
HDAC11 Q96DB2 1/20 0.45
HDAC8 Q9BY41 1/20 0.45
HDAC6 Q9UBN7 1/20 0.45
HDAC9 Q9UKV0 1/20 0.45
HDAC5 Q9UQL6 1/20 0.45
AKR1C3 P42330 3/20 0.44
AKR1C2 P52895 2/20 0.44
AKR1C1 Q04828 2/20 0.44
ALDH1A1 P00352 2/20 0.44
HTT P42858 1/20 0.44
CYP1A2 P05177 1/20 0.43
MEN1 O00255 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4606493 1.00 GRIK1 (0.53) GRIK1CYP2C9HDAC3HDAC4HDAC1
SCHEMBL11335306 0.89 GRIK1 (0.59) GRIK1CYP2C9HDAC3HDAC4HDAC1
SCHEMBL321287 0.89 GRIK1 (0.59) GRIK1CYP2C9HDAC3HDAC4HDAC1
Hydrochloric Acid SCHEMBL27356431 0.88 GRIK1 (0.58) GRIK1CYP2C9HDAC3HDAC4HDAC1
SCHEMBL3857147 0.85 GRIK1 (0.55) GRIK1CYP2C9HDAC3HDAC4HDAC1
SCHEMBL3857149 0.85 GRIK1 (0.55) GRIK1CYP2C9HDAC3HDAC4HDAC1
SCHEMBL15955485 0.84 CYP3A4 (0.55) CYP2C9AKR1C3AKR1C1ALDH1A1HTT
SCHEMBL15955486 0.84 CYP3A4 (0.55) CYP2C9AKR1C3AKR1C1ALDH1A1HTT
SCHEMBL502440 0.83 KMT2A (0.49) CYP2C9AKR1C3ALDH1A1CYP1A2MEN1
SCHEMBL502439 0.83 KMT2A (0.49) CYP2C9AKR1C3ALDH1A1CYP1A2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1946777-A1 Substituted pyrazoline for preventing weight gain Laboratorios del Dr. Esteve S.A. (ES) 2008-07-23 EP disclosed
EP-1946778-A1 Active substance combination for the treatment of diabetes Laboratorios del Dr. Esteve S.A. (ES) 2008-07-23 EP disclosed
US-20070073056-A1 4-Substituted Pyrazoline Compounds, their Preparation and Use as Medicaments LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2007-03-29 US disclosed
US-20070073056-A1 4-Substituted Pyrazoline Compounds, their Preparation and Use as Medicaments LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2007-03-29 US disclosed
US-20070073056-A1 4-Substituted Pyrazoline Compounds, their Preparation and Use as Medicaments LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2007-03-29 US disclosed
WO-2007009689-A1 4,5-DIHYDR0-1H-PYRAZOLE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS LABORATORIOS DEL DR.ESTEVE, S.A. (ES) 2007-01-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070073056-A1 4-Substituted Pyrazoline Compounds, their Preparation and Use as Medicaments P2RX4, PIR, P2RY4 GRIK1 413/4885CYP2C9 322/4885HDAC3 401/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.